Several clinical trials are currently evaluating the efficiency of the adoptive transfer of TIL in combination with anti-PD-1/PD-L1-specific antibodies, in melanoma and other solid tumors (clinicaltrial.gov). This evidence concerns the gene CD274 and melanoma.